Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Molecular Neurodegeneration is Scopus-indexed (Q1, CiteScore 25.1), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by BioMed Central Ltd.
Checked against the index lists dated .
ISSN 1750-1326Verify ISSN ↗
Publisher: BioMed Central Ltd
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Neurology (clinical) | 5 / 403 | 98th | Q1 |
| Cellular and Molecular Neuroscience | 3 / 102 | 97th | Q1 |
| Molecular Biology | 12 / 414 | 97th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q1, CiteScore 25.1.
Molecular Neurodegeneration is Q1 in Neurology (clinical) (rank 5 of 403), Q1 in Cellular and Molecular Neuroscience (rank 3 of 102) and Q1 in Molecular Biology (rank 12 of 414), by CiteScore 2025.
Molecular Neurodegeneration is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 25.1, which places it in quartile Q1 at the 98th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 6.262, quartile Q1, with an H-index of 139.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$3,090 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Molecular Neurodegeneration is published by BioMed Central Ltd. Its ISSN is 1750-1326.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Molecular Neurodegeneration has an h-index of 169 and a 2-year mean of 18.3 citations per paper (OpenAlex). Its Scopus CiteScore is 25.1, quartile Q1. On 2-year citations it ranks #1 of 403 Scopus journals in Neurology (clinical).
Molecular Neurodegeneration published 130 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from United States (44.3%), China (17.4%) and Canada (4.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 8 retracted papers are recorded (5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.